- United States
- /
- Trade Distributors
- /
- NasdaqGM:TRNS
Transcat, Inc. Just Missed EPS By 42%: Here's What Analysts Think Will Happen Next
It's been a sad week for Transcat, Inc. (NASDAQ:TRNS), who've watched their investment drop 18% to US$60.97 in the week since the company reported its second-quarter result. Results overall were not great, with earnings of US$0.14 per share falling drastically short of analyst expectations. Meanwhile revenues hit US$82m and were slightly better than forecasts. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Following the latest results, Transcat's five analysts are now forecasting revenues of US$327.5m in 2026. This would be a solid 8.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to increase 3.5% to US$1.26. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$323.4m and earnings per share (EPS) of US$1.16 in 2026. So the consensus seems to have become somewhat more optimistic on Transcat's earnings potential following these results.
See our latest analysis for Transcat
There's been no major changes to the consensus price target of US$107, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Transcat at US$116 per share, while the most bearish prices it at US$95.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Transcat's rate of growth is expected to accelerate meaningfully, with the forecast 17% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 11% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.8% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Transcat to grow faster than the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Transcat following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Transcat going out to 2028, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 1 warning sign for Transcat you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Transcat might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:TRNS
Transcat
Provides calibration and laboratory instrument services in the United States, Canada, and internationally.
Adequate balance sheet with moderate growth potential.
Similar Companies
Market Insights
Community Narratives

